Aileron Therapeutics, Inc. — Form 10-Q Summary
Filing identity: The supplied filing is for Aileron Therapeutics, Inc. (Nasdaq: ALRN), not Rein Therapeutics, Inc. It covers the unaudited quarter ended March 31, 2023, filed May 8, 2023.
Business Context and Reporting Period
Aileron was a clinical-stage oncology company developing ALRN-6924, an MDM2/MDMX dual inhibitor. In February 2023, the company terminated its Phase 1b breast-cancer chemoprotection trial and discontinued further development of ALRN-6924 after patients experienced Grade 4 severe neutropenia and alopecia. The company reduced its workforce from nine to three employees and began evaluating strategic alternatives, including an acquisition, merger, business combination, asset sale, dissolution, or liquidation.
The company has no approved products, no products under development, and no product revenue. Following expiration of its office sublease on March 31, 2023, it is operating virtually.
Financial Results and Liquidity
| Metric | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.810 million | $5.893 million |
| General and administrative expense | $2.179 million | $2.528 million |
| Restructuring and other costs | $1.022 million | $0 |
| Total operating expenses | $5.011 million | $8.421 million |
| Operating loss | $5.011 million | $8.421 million |
| Net loss | $4.779 million | $8.422 million |
| Basic and diluted loss per share | $1.05 loss | $1.86 loss |
| Cash used in operating activities | $4.661 million | $7.800 million |
Because revenue was zero, operating and net profit margins are not meaningful. As of March 31, 2023, cash and cash equivalents were $7.783 million, investments were $8.938 million, and cash, cash equivalents and investments totaled $16.721 million. Total assets were $17.157 million, total liabilities were $2.884 million, and stockholders’ equity was $14.273 million. The filing does not disclose outstanding debt; liabilities were primarily accounts payable, accrued expenses, and restructuring obligations.
Cash increased by $2.589 million during the quarter, primarily because $7.250 million of investment maturities and sales exceeded $4.661 million of operating cash use. There was no financing cash flow. The company had an accumulated deficit of $277.564 million.
Material Changes Versus the Prior Comparable Period
- Research and development expense decreased $4.083 million, or approximately 69%, primarily because of lower spending on completed clinical trials, manufacturing, and the healthy-volunteer study.
- General and administrative expense decreased $0.349 million, or approximately 14%, primarily due to lower headcount costs.
- Restructuring charges of $1.022 million were recorded in 2023, including severance and related workforce-reduction costs. Approximately $0.992 million remained accrued at quarter-end and was expected to be paid through the second quarter of 2023.
- Net loss improved by $3.643 million, from $8.422 million to $4.779 million.
- Operating cash use decreased by $3.139 million, from $7.800 million to $4.661 million.
- Interest income increased to $55,000 from $21,000, and other income was $177,000 compared with other expense of $22,000 in the prior-year quarter.
- Shares outstanding were 4,541,167 at March 31, 2023, unchanged from December 31, 2022.
Guidance, Outlook, Risks, and Unusual Items
Management expects operating expenses to decline following discontinuation of ALRN-6924 development and the workforce reduction. However, the company stated that anticipated savings may not be fully realized and that future cash requirements depend substantially on the strategic-alternatives process, trial closeout costs, and public-company expenses.
Management concluded that substantial doubt exists about the company’s ability to continue as a going concern for twelve months after issuance of the financial statements. The company stated that it may need additional funding and that, if a strategic transaction is not completed, the board may consider dissolution and liquidation or bankruptcy protection. The filing states that stockholders could receive little or no distribution in a liquidation or bankruptcy.
The company’s equity line with Lincoln Park Capital was unavailable because its stock price was below the $6.00 floor price, and management did not expect to access it in the foreseeable future. No shares were sold under the equity line or ATM facility during the quarter.
Other key risks include the uncertain timing and terms of any strategic transaction, continued cash consumption, potential dilution from future financing, Nasdaq listing compliance, dependence on remaining personnel, intellectual-property obligations, and the absence of a commercial product or revenue stream. No material legal proceedings were reported, and management stated that disclosure controls were effective as of March 31, 2023.
Important Facts for Investors to Verify
- Confirm the filing issuer: the source document identifies Aileron Therapeutics, Inc., whereas the request identifies Rein Therapeutics, Inc.
- Track cash burn, investment maturities, and the remaining $16.721 million of cash, cash equivalents, and investments against the company’s going-concern assessment.
- Monitor whether management completes an acquisition, merger, asset sale, or other strategic transaction, and on what terms.
- Review potential dissolution, liquidation, or bankruptcy outcomes and the amount of cash that may remain available for stockholders after obligations and contingencies.
- Verify the timing and final amount of workforce-reduction payments and other restructuring costs.
- Assess the impact of discontinued ALRN-6924 development on intellectual-property licenses, trial-closeout obligations, and future operating expenses.
- Review Nasdaq listing status and the availability of future equity financing, including the ATM facility and Lincoln Park Capital arrangement.